Communiqués Pfizer Cinnober Boat

Actions

PFZ

US7170811035

Produits pharmaceutiques

Temps Différé Cinnober Boat			Varia. 5j.	Varia. 1 janv.
- ^EUR	-.--%		-.--%	-

08/10	Pfizer Inc. : Jefferies à l'achat	ZD
08/10	Pfizer Inc. : Cantor Fitzgerald reste à l'achat	ZM

Communiqués

07/10	Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer	BU
07/10	Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026	PR
06/10	Pfizer Declares Fourth-Quarter 2026 Dividend	BU
05/10	Pfizer's LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo	AQ
02/10	Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo	BU
01/10	Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study	BU
28/09	Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO	BU
22/09	Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts	BU
15/09	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference	BU
08/09	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference	BU
27/08	Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine	BU
14/08	Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency	AQ
04/08	Pfizer: Q2 Earnings Snapshot	AQ
04/08	Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance	BU
30/07	Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo	BU
29/07	European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union	BU
22/07	FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer	BU
16/07	AM Best Affirms Credit Ratings of Blue Whale Re Ltd	AQ
13/07	“2” Does Not Provide Written Description Support For “1”: Federal Circuit Affirms District Court’s Invalidation Of Patent	AQ
10/07	Pfizer : U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin EligibilityPrescription MedicinesMedicines	PU
10/07	U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility	BU
06/07	“A One-Carbon Poison Pill”: Enanta v. Pfizer And The “Typo” That Lost A Priority Date	AQ
24/06	Pfizer Declares Third-Quarter 2026 Dividend	BU
24/06	Pfizer : FDA Approves Pfizer’s IBRANCE Regimen for HR , HER2 Metastatic Breast Cancer Frontline Maintenance	PU
24/06	FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance	BU